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Introduction: Studies on the role of programmed death-1(PD-1) and its main ligand (PD-L1) during experimental
models of sepsis have shown that the PD-1/PD-L1 pathway plays a pathologic role in altering microbial clearance,
the innate inflammatory response and accelerated apoptosis in sepsis. However, the expression of PD-1 and PD-L1
and their role during the development of immune suppression in septic patients have not been elucidated. The
present study was designed to determine whether the expression of PD-1 and PD-L1 is upregulated in septic
shock patients and to explore the role of this pathway in sepsis-induced immunosuppression.
Methods: Nineteen septic shock patients and 22 sex-matched and age-matched healthy controls were
prospectively enrolled. Apoptosis in lymphocyte subpopulations and PD-1/PD-L1 expression on peripheral T cells, B
cells and monocytes were measured using flow cytometry. Apoptosis of T cells induced by TNFa or T-cell receptor
ligation in vitro and effects of anti-PD-L1 antibody administration were measured by flow cytometry. CD14
+
monocytes of septic shock patients were purified and incubated with either lipopolysaccharide, anti-PD-L1
antibody, isotype antibody, or a combination of lipopolysaccharide and anti-PD-L1 antibody or isotype antibody.
Supernatants were harvested to examine production of cytokines by ELISA.
Results: Compared with healthy controls, septic shock induced a marked increase in apoptosis as detected by the
annexin-V binding and active caspase-3 on CD4
+ T cells, CD8
+ T cells and CD19
+ B cells. Expression of PD-1 on T
cells and of PD-L1 on monocytes was dramatically upregulated in septic shock patients. PD-1/PD-L1 pathway
blockade in vitro with anti-PD-L1 antibody decreased apoptosis of T cells induced by TNFa or T-cell receptor
ligation. Meanwhile, this blockade potentiated the lipopolysaccharide-induced TNFa and IL-6 production and
decreased IL-10 production by monocytes in vitro.
Conclusions: The expression of PD-1 on T cells and PD-L1 on monocytes was upregulated in septic shock
patients. The PD-1/PD-L1 pathway might play an essential role in sepsis-induced immunosuppression.
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Sepsis, a systemic inflammatory response to infection,
kills more than 210,000 people in the United States
annually [1] and remains one of the most challenging
clinical problems worldwide, constituting the leading
cause of death in noncoronary intensive care units
(ICUs) [2].
Sepsis initiates a complex immunologic response that
varies over time with the concomitant occurrence of both
proinflammatory and anti-inflammatory mechanisms
alternatively predominating. After a short proinflamma-
tory phase, septic patients enter a stage of protracted
immunosuppression, which is an important underlying
cause of mortality during the late stage of sepsis. This
immunosuppression in sepsis is clinically manifest by
cutaneous anergy, hypothermia, leucopenia, susceptibility
to infection, and failure to clear infection [3-5].
Monocytes play an essential role in the innate immune
defense against microbial infection. Septic immunopara-
lysis is first characterized by a monocytic deactivation of
phagocytic function, proinflammatory cytokine release,
and antigen-presenting capacity (probably due to a
decreased expression of HLA-DR) [6,7]. Importantly, the
persistence of immunoparalysis, is correlated with an
increased risk of fatal outcomes [8]. On the other hand,
accumulating evidence points to the pivotal role of
increased immune effector cell apoptosis in sepsis-
induced immunosuppression [9,10]. Uptake of apoptotic
cells by macrophages and dendritic cells (DCs) stimu-
lates immune tolerance by inducing the release of anti-
inflammatory cytokines, including IL-10 and transform-
ing growth factor beta, and suppressing the release of
proinflammatory cytokines. Inhibition of lymphocyte
apoptosis can improve survival in animal models of sep-
sis by using selective caspase inhibitors [11,12], by alter-
ing proapoptotic/antiapoptotic protein expression
[13,14], and by treatment with survival-promoting cyto-
kines such as IL-7 [15] and/or IL-15 [16].
Sepsis produces marked alterations in the expression of
membrane-associated co-stimulatory/inhibitory molecules.
Expression of these accessory molecules appears to contri-
bute to the morbidity/mortality seen not only in acute
models of lethal septic challenge but in patients with septic
shock [17,18]. Programmed death-1 (PD-1) is a newly iden-
tified co-inhibitory receptor. PD-1 has two main ligands–
PD-L1 (B7-H1) and PD-L2 (B7-DC) [19]. PD-1 and its
ligands exert inhibitory effects in the setting of persistent
antigenic stimulation by regulating the balance between
T-cell activation, tolerance, and immunopathology. The
PD-1/PD-L1 pathway has been shown to be a crucial mod-
ulator of host immune responses in regulation of autoim-
munity, tumor immunity, transplantation immunity,
allergy, immune privilege, and ischemia/reperfusion injury
[20]. Recent findings suggest that the PD-1/PD-L1 pathway
plays an important role in the interaction between host
a n dp a t h o g e n i cm i c r o b e st h a te v o l v e dt or e s i s ti m m u n e
responses. Those pathogens include viruses [21], certain
bacteria [22], fungi [23], and some worms [24].
Some work has been carried out on the role of the
PD-1/PD-L1 pathway in a model of sepsis, which
showed that the pathway played a pathologic role in
altering microbial clearance, the innate inflammatory
response, and accelerated apoptosis in sepsis [25,26].
Huang and colleagues showed that PD-1 deficiency pro-
tects mice from the lethality of sepsis by balancing effi-
cient pathogen clearance and inflammatory cytokine
production [25]. Brahmamdam and colleagues showed
that the administration of anti-PD-1 antibody 24 hours
after cecal ligation and puncture (CLP)-induced sepsis
prevented sepsis-induced depletion of lymphocytes and
DCs, increased the expression of Bcl-xL, inhibited apop-
tosis, and improved survival, indicating that PD-1 block-
ade is a potential promising therapeutic target for sepsis
[26]. Our recent work showed that expression of PD-1
on T cells, B cells and monocytes, and expression of
PD-L1 on B cells and monocytes, were upregulated in
septic mice compared with sham-operated controls. PD-
L1 blockade significantly improved survival of CLP mice
by preventing sepsis-induced depletion of lymphocytes,
increasing TNFa and IL-6 production, decreasing IL-10
production, and enhancing bacterial clearance [27].
Brahmamdam and colleagues also showed that there is
an increase of PD-1 expression on CD4 and CD8 cells
after CLP-induced sepsis [26]. Huang and colleagues
demonstrated that PD-1 expression on circulating
monocytes was higher in patients with septic shock than
in healthy volunteers [25]. Only five patients were
included in the study, however, and the change of PD-1
expression in patients with sepsis was not the main
objective in their study. In other words, the expression
of PD-1 and PD-L1 and their role have not been eluci-
dated in patients with sepsis. In this article, we present
a cohort study designed to determine the expression
changes of PD-1 and PD-L1 in septic shock patients.
Materials and methods
Patients and controls
The present study was conducted with approval from
the ethics board of the Second Military Medical Univer-
sity, China. Patients were included after written
informed consent signed by them or their next of kin.
Nineteen consecutive patients with septic shock were
prospectively included according to the diagnostic cri-
teria of the American College of Chest Physicians/
Society of Critical Care Medicine [28]. Patients were
admitted to the surgical ICU of the Changhai Hospital,
Second Military Medical University (Shanghai, China).
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Page 2 of 9of vasopressive therapy. The exclusion criteria included
a lack of informed consent, age under 18 years, pre-
existing hematological or immunological disease, and
the absence of circulating leukocytes.
Patients were treated according to the standardized
recommendations of our ICU. Arterial blood samples
were obtained from each patient on the day of inclusion.
After blood sampling in the ICU, tubes were transported
at 4°C to the clinical research center within 2 hours for
the measurement of apoptosis and expression of PD-1
and PD-L1. Flow cytometry staining was first performed
as described below. The remaining blood was then pro-
cessed to isolate peripheral blood mononuclear cells
(PBMCs) by Ficoll density gradient centrifugation
(within 3 hours) and CD14
+ monocyte purification. To
provide panels of control values for flow cytometry ana-
lysis, 22 sex-matched and age-matched healthy indivi-
duals (age 58.6 ± 4.3 years; 11 females, 11 males) with
no known co-morbidities were also included.
Apoptosis measurements by flow cytometry
One hundred microliters of whole blood were subjected
to VersaLyse lysing solution (Beckman-Coulter, Hialeah,
F L ,U S A )f o r1 5m i n u t e sa tr o o mt e m p e r a t u r e .A f t e r
washing, cells were incubated with phycoerythrin-
labeled antibodies directed against CD4, CD8 and CD19.
Apoptosis induction in each specific lymphocyte subpo-
pulation - CD4
+ T cells, CD8
+ T cells and CD19
+ B
cells - was assessed using annexin-V binding and intra-
cellular active caspase-3 measurements.
Regarding the annexin-V binding experiments, accord-
ing to the manufacturer’s protocol, lysed samples were
incubated for 15 minutes with phycoerythrin-labeled
annexin-V (Annexin-V-PE Apoptosis Detection Kit; BD
Biosciences, San Jose, CA, USA) and measured on a
flow cytometer within 30 minutes using CellQuest soft-
ware version 3.2 (BD Biosciences, San Jose, CA, USA).
Results are expressed as percentages of respective cell
populations positive for annexin-V binding. A threshold
for positivity was set up based on nonstained controls.
For active caspase-3 intracellular staining, following
two washes, lymphocytes were fixed and permeabilized
using Cytofix/Cytoperm reagent (BD Biosciences) and
were incubated with phycoerythrin-labeled anti-active
caspase-3 antibodies (BD Biosciences). Isotype control
antibodies were used to determine nonspecific binding.
After one further wash, cells were analyzed by flow cyto-
metry. Results are expressed as percentages of respective
cell populations positive for caspase-3.
PD-1 and PD-L1 expression on peripheral T cells, B cells
and monocytes
Blood samples were obtained from 19 septic patients
and 22 healthy controls. After erythrocytes were lysed
using fluorescence-activated cell sorting lysing solution
(BD Bioscience), cells were stained with fluorochrome-
conjugated anti-CD3, anti-CD19, anti-CD14, anti-PD-1
or anti-PD-L1 antibodies. Flow cytometric analysis
(50,000 events/sample) was performed on a FACSCali-
bur Flow Cytometer (BD Biosciences) using CellQuest




+ cells or CD14
+ cells,
respectively.
Antibodies were purchased from eBioscience (San Jose,
CA, USA): CD4-FITC (Clone RPA-T4, catalog num-
ber 12-0049), CD8-APC (Clone RPA-T8, catalog
number 17-0088), CD19-PE-Cy5 (Clone HIB19,
catalog number 15-0199), CD14-FITC (Clone 61D3,
catalog number 11-0149), PD-1-PE (Clone MIH4, catalog
number 12-9969), and PD-L1-PE (Clone MIH1, catalog
number 12-5983).
Induction of T-cell apoptosis and PD-L1 blockade in vitro
PBMCs were separated from whole blood of septic
patients using standard gradient centrifugation with Lym-
phocyte Separation Medium (PAA Laboratories GmbH,
Pasching, Austria) and were cultured at 4 × 10
5 cells/well
in plates. Apoptosis was analyzed by flow cytometry after
addition of 10 ng/ml TNFa (Peprotech, Rocky Hill, NJ,
USA) alone or with anti-PD-L1 antibody (10 μg/ml, Clone
MIH1, catalog number 16-5983; eBioscience) or isotype
(10 μg/ml) for 18 hours. Alternatively, PBMCs were trea-
ted with 10 μg/ml anti-CD3 and 5 μg/ml anti-CD28
(eBioscience) alone or with anti-PD-L1 antibody (10 μg/
ml) or isotype (10 μg/ml) for 72 hours. Cells were double-
stained with annexin V and propidium iodide, with gating
on CD3-positive cells, and were analyzed by fluorescence-
activated cell sorting. Apoptosis was calculated as the per-
centage of annexin V-positive/propidium iodide-negative
cells after gating on CD3-positive cells.
Purification of human CD14
+ monocytes,
lipopolysaccharide stimulation and PD-L1 blockade in
vitro
PBMCs were separated from whole blood of septic
patients and CD14
+ monocytes were purified using
immunomagnetic beads coated with anti-CD14 mono-
clonal antibody (Miltenyi Biotec. Bergisch Gladbach,
Germany) as previously described by Saikh and collea-
gues [29]. Flow cytometry analysis of the purified popu-
lation demonstrated that more than 95% was positive
for CD14 expression. CD14
+ monocytes were incubated
with either lipopolysaccharide (100 ng/ml), anti-PD-L1
antibody (10 μg/ml), isotype antibody (10 μg/ml), or a
combination of lipopolysaccharide (100 ng/ml) and anti-
PD-L1 antibody (10 μg/ml) or isotype antibody (10 μg/
ml). Twenty-four hours later, supernatant was harvested
to detect cytokine production such as TNFa,I L - 6 ,a n d
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tions (R&D Systems, Minneapolis, MN, USA).
Statistical analysis
Data are reported as the mean ± standard error of the
mean. All statistical analyses were carried out with Prism
4 . 0( G r a p h P a dS o f t w a r e ,L aJ o l l a ,C A ,U S A ) .C o m p a r i -
sons between healthy controls and septic shock patients
were made using the nonparametric Mann-Whitney U
test with P < 0.05 considered statistically significant.
Results
Characteristics of the septic patient cohort
Nineteen patients with septic shock (nine women and
10 men) and 22 healthy volunteers (sex-matched and
age-matched) were enrolled in the current study. The
demographic and clinical characteristics of the cohort
a r ep r e s e n t e di nT a b l e1 .N o n eo ft h es e p t i cs h o c k
patients were previously immunocompromised (HIV,
cancer, immunosuppressive treatments). Patients did not
receive drotrecogin alfa (activated) before or during
their treatment. Six patients received adjunctive corti-
costeroid treatment (3 mg/kg hydrocortisone) before or
at the time of sampling. Nine septic shock patients died
during their ICU stay.
Underlying diseases of the septic shock group were
necrotizing fasciitis (n = 3), fecal peritonitis (n = 9), and
pneumonia (n = 7). The total number of leukocytes was
increased in septic patients compared with healthy
volunteers. In contrast, the total lymphocyte cell count
was significantly diminished in shock patients compared
with normal values.
Annexin-V binding and caspase-3 activation measured by
flow cytometry
We further assessed apoptosis (annexin-V binding and
active caspase-3) by flow cytometry. We observed a
significant increase of annexin-V binding on CD4
+ T
cells, CD8
+ T cells and CD19
+ B cells in septic shock
patients (Figure 1a).
Caspase-3 is the central executioner caspase. Activa-
tion of caspase-3 leads to degradation of multiple intra-
cellular substrates and to the typical morphological
features of classical apoptosis. In patients with septic
shock, the subpopulation with active caspase-3 was ele-
vated in CD4
+ T cells, CD8
+ T cells and CD19
+ B cells
compared with healthy controls (Figure 1b).
Expression of PD-1 and PD-L1 measured by flow cytometry
PD-1 and PD-L1 expression on T cells, B cells and
monocytes in peripheral blood from septic patients was
measured (Figure 2). The results showed that expression
of PD-1 on both CD4
+ T cells and CD8
+ Tc e l l si n






Age at admission (years) 58 ± 4 59 ± 4
Gender (male) 10 11
APACHE II score at inclusion 26 ± 3 NA
SAPS II score at inclusion 55 ± 3 NA
Mechanically ventilated at inclusion (n)1 6 N A
Antibiotic treatment at inclusion (n)1 6 N A
Adjunctive corticosteroid treatment
a (n)6 N A
White blood cell count at inclusion (g/l) 15.6 ± 2.8 6.5 ± 1.7
Lymphocyte count at inclusion (g/l) 0.92 ± 0.21 1.6 ± 0.8
Mortality (n)9 0
Data presented as n or the mean ± standard error. APACHE, Acute Physiology
and Chronic Health Evaluation; NA, not applicable; SAPS, Simplified Acute
Physiology Score.
aHydrocortisone, before or at the time of sample acquisition.
Figure 1 Confirmation of accelerated apoptosis in septic shock




lymphocytes of patients with septic shock. The population of
annexin-V binding lymphocytes increased. *P < 0.01 compared with
healthy controls. (b) Detection of active caspase-3 in lymphocyte
populations. In patients with severe sepsis, the percentage of active
caspase-3 positive lymphocytes (CD4
+ T cells, CD8
+ T cells, CD19
+ B
cells) increased. *P < 0.01 compared with healthy controls.
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healthy control cells (4.63-fold and 2.37-fold, P <0 . 0 1 )
(Figure 2a, b). PD-1 expression was verified by the mean
fluorescence intensity and showed similar results (P <
0.05) (Figure 2d, e). We also demonstrated that PD-L1
was dramatically upregulated on monocytes (3.58-fold, P
< 0.01) compared with healthy subjects (Figure 2c, f) (P
<0 . 0 1 ) .T h e r ew a sn oc h a n g eo fP D - 1e x p r e s s i o no n
either B cells (CD19
+) or monocytes (CD14
+). There
was no change of PD-L1 expression on either T cells
(CD4
+ and CD8
+) or B cells (CD19
+)( d a t an o ts h o w n ) .
Our data indicated that in addition to PD-1 upregula-
tion on T cells, PD-L1 levels on monocytes also
increased significantly.
Effect of PD-L1 blockade on induced T-cell apoptosis in vitro
To investigate the potential role of PD-1/PD-L1 on T-
cell apoptosis in sepsis, we induced the apoptosis under
stimulation with exogenous recombinant TNFa or anti-
C D 3a n da n t i - C D 2 8l i g a t i o n .W ef o u n dt h a tP D - L 1
blockade significantly induced a decrease of T-cell apop-
tosis. Cells treated with anti-PD-L1 antibody had an
approximately 50% reduction in septic-shock-induced
apoptosis in CD4 and CD8 T cells compared with the
isotype control antibody-treated population in both
TNFa-induced and T-cell receptor-induced apoptosis
(Figure 3). Our results suggest that blockade of the PD-
1/PD-L1 pathway could decrease human peripheral T-
cell apoptosis.
Effect of PD-L1 blockade on cytokine production of
monocytes from septic shock patients in vitro
To assess the effect of the PD-1/PD-L1 pathway block-
ade on cytokine production of monocytes from septic
shock patients in vitro,C D 1 4
+ monocytes were isolated
and purified from PBMCs and pretreated with anti-PD-
L1 antibody or isotype control antibody before lipopoly-
saccharide stimulation. Supernatants were harvested
after 24 hours to detect cytokine production by ELISA.
We found that PD-L1 blockade enhanced the capacity
of monocytes to produce proinflammatory cytokines,
such as TNFa and IL-6 (Figure 4a, b), compared with
isotype control antibody-treated cells. In contrast, IL-10
production was decreased significantly as compared
with isotype control antibody-treated cells (Figure 4c).
These results suggest that PD-1/PD-L1 pathway block-
a d eb ya n t i - P D - L 1a n t i b o d yi m p r o v e dt h ef u n c t i o no f
monocytes isolated from septic patients.
Figure 2 PD-1 and PD-L1 were upregulated on T cells and monocytes in septic shock patients. Blood samples were obtained from 19
septic shock patients and 22 healthy controls and were stained for programmed death-1 (PD-1) and programmed death ligand-1 (PD-L1) gated
on CD4
+ T cells, CD8
+ T cells, and CD14
+ monocytes. (a) to (c) Percentage of PD-1 expression on (a) CD4
+ T cells and (b) CD8
+ T cells, and (c)
percentage of PD-L1 expression on CD14
+ monocytes. Each dot represents one individual. Data are mean ± standard error of the mean (SEM) of
three independent experiments. **P < 0.01 compared with healthy controls. (d) to (f) Mean fluorescence intensity (relative fluorescence units) of
PD-1 expression on (d) CD4
+ T cells, (e) PD-1 expression on CD8
+ T cells, and (f) PD-L1 expression on CD14
+ monocytes Each dot represents one
individual. Data are mean ± SEM of three independent experiments. *P < 0.05 compared with healthy controls. (g) Representative PD-1
expression levels on CD4
+ T cells and CD8
+ T cells, and PD-L1 expression on CD14
+ monocytes. Values in the upper-right quadrant indicate the
percentage of cells that express PD-1 or PD-L1.
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The current study demonstrates that PD-1 on T cells
and PD-L1 on monocytes are upregulated dramatically
in a cohort of septic shock patients exhibiting acceler-
ated lymphocyte apoptosis as compared with healthy
controls. To our best knowledge, this is the largest num-
ber of patients specifically focused on to study PD-1 and
PD-L1 expression in patients with sepsis. The patients
with septic shock in the study exhibited accelerated
apoptosis of all major lymphocyte subpopulations. The
degree of apoptosis as indicated by annexin-V binding
and caspase-3 activation was comparable with findings
from previous reports [30-32]. The septic cohort of this
study thus exhibited a degree of typical apoptosis of sep-
tic shock. PD-1 and its two known agonistic ligands,
PD-L1 (B7-H1) and PD-L2 (B7-DC), are regulated by
Figure 3 Blockade of the PD-1/PD-L1 pathway by anti-PD-L1 antibody. Blockade of the programmed death-1 (PD-1)/programmed death
ligand-1 (PD-L1) pathway by anti-PD-L1 antibody decreased apoptosis of human peripheral T cells from septic patients induced by TNFa and by
T-cell receptor ligation. (a) Peripheral blood mononuclear cells were obtained from septic shock patients and cultured at 4 × 10
5 per well in
plates precoated with 10 ng/ml TNFa (Peprotech) alone or with anti-PD-L1 antibody(10 μg/ml) or isotype (10 μg/ml) for 18 hours to analyze
apoptosis by flow cytometry. Alternatively, peripheral blood mononuclear cells were treated with 10 μg/ml anti-CD3 and 5 μg/ml anti-CD28
alone or with anti-PD-L1 antibody (10 μg/ml) or isotype (10 μg/ml) for 72 hours. Cells were doubled-stained with annexin V and propidium
iodide (PI) with gating on CD3
+ cells and were analyzed by fluorescence-activated cell sorting. Apoptosis was calculated as the percentage of
annexin V-positive/PI-negative cells after gating on CD3
+ cells. *P < 0.05 compared with control group. (b) Representative micrographs from six
independent experiments. Representative data showing apoptosis of CD3
+ T cells.
Figure 4 Effect of anti-PD-L1 antibody treatment. Anti-programmed death ligand-1 (anti-PD-L1) antibody treatment improved the ability of
monocytes from septic shock patients to produce proinflammatory cytokines and decreased production of anti-inflammatory cytokines in vitro.
(a) to (c) Peripheral blood mononuclear cells were separated from whole blood of septic patients and CD14
+ monocytes were purified using
immunomagnetic beads coated with anti-CD14 monoclonal antibody. CD14
+ monocytes were incubated with either lipopolysaccharide (LPS)
(100 ng/ml), anti-PD-L1 antibody (10 μg/ml), isotype antibody (10 μg/ml), or a combination of LPS (100 ng/ml) and anti-PD-L1 antibody (10 μg/
ml) or isotype antibody (10 μg/ml) for 24 hours. The supernatants were collected for ELISAs of (a) TNFa, (b) IL-6 and (c) IL-10. Data are mean ±
standard error of the mean of three independent experiments. *P < 0.05, **P < 0.01.
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types. Naïve T cells do not express PD-1, which is
induced following engagement of the T-cell receptor.
PD-1 remains expressed, however, on the surface of
memory T cells. PD-L1 is present on multiple immune
cells, including T cells and B cells, monocytes, DCs and
macrophages, as well as on nonimmune cells, whereas
PD-L2 expression is more restricted, present on acti-
vated DCs and macrophages [19,20]. Our study demon-
strates that PD-1 on T cells and PD-L1 on monocytes
are upregulated dramatically in septic shock patients.
There was no change, however, of PD-1 expression on
either B cells (CD19
+) or monocytes (CD14
+). There
was no change of PD-L1 expression on either T cells
(CD4
+ and CD8
+) or B cells (CD19
+).
Apoptosis of lymphocytes plays a pivotal role in immu-
nosuppression. Multiple independent investigative groups
have shown that the prevention of lymphocyte apoptosis
improves survival in sepsis [11-16]. PD-1 and its ligand,
PD-L1, deliver inhibitory signals that regulate the balance
between T-cell activation, tolerance, and immunopathol-
ogy. The PD-1/PD-L pathway has also been usurped by
pathogens and tumors to attenuate antimicrobial or anti-
tumor immunity, facilitating chronic infection and tumor
survival. Recent work has been carried out on the role of
the PD-1/PD-L1 pathway in a model of sepsis, which
showed that PD-1/PD-L1 blockade is a potential promis-
ing therapeutic target for sepsis [25-27]. Blockade of PD-
1 or PD-L1 results in enhanced T-cell responses, either
through a direct pathway [33-35] or by abrogating the
inhibitory function of regulatory T cells [36]. Herein,
blockade of the PD-1/PD-L1 pathway decreased human
peripheral T-cell apoptosis induced by TNFa and T-cell
receptor ligation in vitro. Our data showed that PD-1 on
T cells also appears to be an important mediator of T-
lymphocyte apoptosis, which results in immunosuppres-
sion during sepsis.
Monocytes rapidly exhibit an impaired production of
proinflammatory cytokines during sepsis although the
underlying mechanism remains elusive [37]. In our study,
we found dramatic upregulation of PD-L1 on monocytes
from septic shock patients. In vitro PD-L1 blockade
enhanced the capacity of monocytes from septic patients
to produce proinflammatory cytokines, such as TNFa and
IL-6, while decreasing the production of anti-inflammatory
cytokines, such as IL-10. Our recent animal work showed
that PD-L1 blockade increased TNFa and IL-6 produc-
tion, and decreased IL-10 production in CLP mice. Taken
together, we thought that the upregulation of PD-L1 on
monocytes from septic shock patients might be associated
with their functional decline, and thus may play an impor-
tant role in immunosuppression [38]. These results also
uncovered a role for PD-L1 that may be of great impor-
tance in the regulation of monocyte function seen during
sepsis and may perhaps provide a novel mechanism
underlying impaired monocyte function during sepsis.
Several limitations should be noted here. The overall
sample size of the study is relatively small and we did
not evaluate the changes of PD-1/PD-L1 expression
over time after septic shock. This change in expression
needs to be investigated in future studies. Another lim-
itation is that the present study was not designed to pre-
dict the morbidity or mortality of septic shock, which
are both also worth further investigation.
Taken together, our findings indicated that both PD-
1 and PD-L1 were involved in sepsis-induced
immunosuppression.
Conclusions
Expression of the PD-1 on T cells and of PD-L1 on
monocytes was upregulated in septic shock patients.
Blocking the PD-1/PD-L1 pathway with anti-PD-L1
antibody resulted in decreased apoptosis of T cells and
improved the ability of monocytes to produce proin-
flammatory cytokines in vitro. These novel findings sug-
gest that the PD-1/PD-L1 pathway might be a useful
target to treat sepsis-induced immunosuppression.
Key messages
￿ Expression of PD-1 on T cells and of PD-L1 on
monocytes was dramatically upregulated in septic
shock patients.
￿ PD-1/PD-L1 pathway blockade in vitro with anti-
PD-L1 antibody decreased apoptosis of T cells
induced by TNFa or T-cell receptor ligation. Mean-
while, this blockade potentiated the lipopolysacchar-
ide-induced TNFa and IL-6 production and
decreased IL-10 production by monocytes in vitro.
￿ The PD-1/PD-L1 pathway might play an essential
role in sepsis-induced immunosuppression.
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